Analyst Ratings For Akcea Therapeutics (NASDAQ:AKCA)
Today, Wells Fargo reiterated its Outperform rating on Akcea Therapeutics (NASDAQ:AKCA) with a price target of $20.00.
Some recent analyst ratings include
- 3/19/2018-Wells Fargo Reiterated Rating of Outperform .
- 2/27/2018-Cowen was Downgraded by analysts at Cowen from a “Outperform ” rating to a ” Market Perform” rating.
- On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.
Recent Trading Activity for Akcea Therapeutics (NASDAQ:AKCA)
Shares of Akcea Therapeutics closed the previous trading session at with 29.700000762939453 shares trading hands.